Latest news and press releases about Shuttle Pharmaceuticals Holdings, Inc. (SHPH): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Price
| Price | $3.13 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.47 |
| EV / EBITDA | -0.12 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -408.33% |
| Return on Invested Capital | -312.04% |
| Return on Assets | -91.63% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AKAN · BBLG · BIVI · HSCS · IMCC · ISPC · MSPR
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SHPH: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks